Key facts
- National Resilience is closing six facilities.
- A subsidiary has filed for Chapter 11 bankruptcy protection.
- The company cited a biotech slowdown and capacity mismatch.
National Resilience, a CDMO startup, is closing six of its facilities as part of a strategic streamlining effort amid a biotech slowdown. The company's CEO, William Marth, informed customers that sites not being fully utilized would be wound down. A subsidiary of the company has filed for Chapter 11 bankruptcy protection. The affected facilities are located in Alachua, Florida; Fremont and San Diego, California; and Allston, Bedford, and Marlborough, Massachusetts. However, the company's packaging and fill/finish site in Cincinnati, GMP manufacturing site in Toronto, cell therapy center of excellence in Philadelphia, and viral vector manufacturing site in Raleigh-Durham will continue to operate. This move follows earlier workforce reductions at its Allston, Alachua, and North Carolina sites in recent years.